SELLAS Life Sciences Group, Inc. — 10-Q Summary
Entity note: The supplied filing identifies the registrant as Galena Biopharma, Inc., not SELLAS Life Sciences Group, Inc. This summary reflects the filing provided. Reporting period: three months ended March 31, 2016; financial statements are unaudited.
Business context and reporting period
Galena described itself as a clinical-stage biopharmaceutical company focused on oncology therapies. Its pipeline included NeuVax, in a pivotal Phase 3 breast cancer trial; GALE-301 and GALE-302, in earlier-stage cancer immunotherapy trials; and GALE-401, in a Phase 2 trial for elevated platelet counts. The company sold its Abstral and Zuplenz commercial businesses in Q4 2015 and reported their remaining results as discontinued operations.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue from continuing operations | None reported | None reported |
| Research and development expense | $5.443 million | $5.825 million |
| General and administrative expense | $3.525 million | $3.087 million |
| Operating loss | $8.968 million | $8.912 million |
| Loss from continuing operations | $13.102 million | $8.306 million |
| Loss from discontinued operations | $3.391 million | $2.231 million |
| Net loss | $16.493 million | $10.537 million |
| Basic and diluted loss per share | $0.09 | $0.08 |
- Cash and cash equivalents were $34.709 million at March 31, 2016, versus $29.730 million at year-end 2015. Total assets were $66.365 million; stockholders’ equity was $12.413 million.
- Operating cash use was $13.216 million, including $9.741 million from continuing operations and $3.475 million from discontinued operations. Investing cash use was $1.056 million; financing provided $19.251 million, principally from the January stock offering. Cash increased $4.979 million during the quarter.
- Current liabilities totaled $42.222 million, including a $23.934 million liability for warrants potentially settleable in cash and a $5.000 million litigation settlement payable. The balance sheet reported $3.740 million as the current portion of long-term debt; the Oxford Finance loan was due in November 2016.
- No operating margin is meaningful given the absence of continuing revenue and the company’s development-stage operations. No income tax expense or benefit was recorded.
Material changes versus the prior comparable period
- Net loss increased 57%, from $10.537 million to $16.493 million. Operating loss was broadly flat, while continuing-operations loss widened largely because warrant fair-value movements shifted from a $1.152 million gain in Q1 2015 to a $3.873 million loss in Q1 2016.
- R&D expense declined 7% as PRESENT trial enrollment ended and the study moved into monitoring; G&A expense rose 14%, including higher stock-based compensation and personnel and recruitment costs.
- Discontinued-operations loss increased to $3.391 million from $2.231 million. Q1 2016 included larger-than-expected Abstral rebates and $2.1 million of external legal expenses related to document requests concerning former sales and marketing practices. Q1 2015 included $2.750 million of discontinued-operations revenue.
- Share count increased: 19.773 million common shares were issued in the January 2016 offering. The offering generated $20.189 million in net proceeds and included warrants.
Outlook, contingencies and risks
- The Phase 3 PRESENT trial was fully enrolled at 758 patients and reached its 70th qualifying disease-free-survival event, triggering a planned interim analysis. Management expected the independent monitoring committee’s analysis and recommendation near the end of Q2 2016. A discontinuation decision could affect both the trial and financing obligations.
- Management expected R&D expense to increase in 2016 as the pipeline expanded, trials progressed, and the company added clinical, quality, safety, data-management and regulatory personnel. It expected ongoing operating losses and said existing cash and available financing sources should fund operations for at least one year, while cautioning that additional funding might be needed and might not be available on acceptable terms.
- On May 10, 2016, after quarter-end, the company issued $25.530 million of 9% senior secured debentures at a 6.375% original issue discount, receiving approximately $23.4 million net, plus warrants for up to 2.0 million shares. The debt matures November 10, 2018, is secured by a senior lien on company assets, and includes cash-maintenance requirements of $24 million through the PRESENT interim-analysis announcement, reduced to $12 million if the trial continues. If the trial is discontinued, the holder may require repayment of funded principal and accrued interest in cash. Proceeds were intended to support trials, repay the Oxford loan and fund working capital and general purposes.
- Litigation settlements totaled $25 million: insurers paid $20 million and paid a further $1.7 million in April; the company expected to pay $2.3 million in cash and $1 million in stock. Final court approval remained pending for the derivative and securities class-action settlements.
- The company disclosed subpoenas and investigations related to Abstral marketing and promotional practices, was cooperating with authorities, and said it could not predict the outcome or potential financial impact. It also cited substantial patent-protection and product-development risks, including limited composition-of-matter protection for key peptides.
- Other notable trial updates included planned initiation of a NeuVax DCIS Phase 2 study and a planned gastric-cancer Phase 2 study in India. Management also planned to discuss GALE-401 development and regulatory strategy with the FDA.
Most important facts for investors to verify
- Confirm the correct issuer: the supplied 10-Q is for Galena Biopharma, not SELLAS Life Sciences Group.
- Verify the PRESENT interim-analysis result, its effect on continuation of the trial, and any related debenture repayment or warrant provisions.
- Track cash use, the $24 million/$12 million cash covenants, debt repayment terms and the company’s actual financing runway.
- Check final approval and payment of the litigation settlements, as well as the status and potential consequences of Abstral-related investigations and legal expenses.
- Assess trial progress, future R&D spending, patent scope and dilution from outstanding warrants, options and financing instruments.